New Zealand markets closed

NVS Oct 2022 85.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
8.100.00 (0.00%)
As of 10:59AM EDT. Market open.
Full screen
Loading interactive chart…
  • Motley Fool

    Could This Biosimilar Drug Candidate Be a Hit for Novartis?

    On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.

  • Zacks

    NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?

    NVS vs. RHHBY: Which Stock Is the Better Value Option?

  • Zacks

    Is Novartis (NVS) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.